These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Evaluation of Responsiveness to Reduced-Dose Rituximab in Corticotropin/Intravenous Immunoglobulin/Rituximab Combination Immunotherapy for Opsoclonus-Myoclonus Syndrome. Pranzatelli MR; Tate ED; McGee NR; MacArthur CA Pediatr Neurol; 2018 Aug; 85():71-75. PubMed ID: 30197220 [TBL] [Abstract][Full Text] [Related]
5. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study. Martinez Del Pero M; Chaudhry A; Jones RB; Sivasothy P; Jani P; Jayne D Clin Otolaryngol; 2009 Aug; 34(4):328-35. PubMed ID: 19673980 [TBL] [Abstract][Full Text] [Related]
13. Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus. Bell J; Moran C; Blatt J Pediatr Blood Cancer; 2008 Feb; 50(2):370-1. PubMed ID: 16652344 [TBL] [Abstract][Full Text] [Related]
14. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482 [TBL] [Abstract][Full Text] [Related]
15. Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments. Battaglia T; De Grandis E; Mirabelli-Badenier M; Boeri L; Morcaldi G; Barabino P; Intra C; Naselli F; Pistoia V; Veneselli E; Conte M Eur J Paediatr Neurol; 2012 Mar; 16(2):192-5. PubMed ID: 21737325 [TBL] [Abstract][Full Text] [Related]